Results 311 to 320 of about 66,239 (358)
Some of the next articles are maybe not open access.
Drugs of Today, 2007
There is a real and viable need in the anticoagulant arena for a safe, robust, effective oral anticoagulant drug that measures up to warfarin in providing protection against thrombosis and compares favorably (if not better) with regard to safety profile, without the need for routine and often cumbersome monitoring.
Puneet, Kakar +2 more
openaire +2 more sources
There is a real and viable need in the anticoagulant arena for a safe, robust, effective oral anticoagulant drug that measures up to warfarin in providing protection against thrombosis and compares favorably (if not better) with regard to safety profile, without the need for routine and often cumbersome monitoring.
Puneet, Kakar +2 more
openaire +2 more sources
American Journal of Otolaryngology, 2015
The objective of this case report is to increase awareness regarding a new category of drugs, new direct oral anticoagulants (specifically, rivaroxaban), which are increasingly being used instead of the more traditional vitamin K antagonists, to highlight the current recommendations for perioperative management of rivaroxaban, and to demonstrate a ...
Victor J. Schorn +2 more
openaire +3 more sources
The objective of this case report is to increase awareness regarding a new category of drugs, new direct oral anticoagulants (specifically, rivaroxaban), which are increasingly being used instead of the more traditional vitamin K antagonists, to highlight the current recommendations for perioperative management of rivaroxaban, and to demonstrate a ...
Victor J. Schorn +2 more
openaire +3 more sources
Annals of Internal Medicine, 2022
BACKGROUND Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.
W. Lau +12 more
semanticscholar +1 more source
BACKGROUND Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.
W. Lau +12 more
semanticscholar +1 more source
Hospital Pharmacy, 2011
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Danial E. Baker +3 more
openaire +2 more sources
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Danial E. Baker +3 more
openaire +2 more sources
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
New England Journal of Medicine, 2012 Eugene Braunwald +2 more
exaly +2 more sources
The discovery and development of rivaroxaban
Annals of the New York Academy of Sciences, 2011Thromboembolic conditions present a considerable challenge to healthcare services because they are associated with substantial morbidity and mortality. The mainstays of prevention and treatment are anticoagulants and antiplatelet agents. Established anticoagulants have drawbacks that make their use difficult to manage and sustain.
Scott D. Berkowitz +2 more
openaire +3 more sources
Phamacokinetics of rivaroxaban in adolescents
Hämostaseologie, 2014SummaryBackground: The direct factor Xa inhibitor rivaroxaban is approved for venous throm-boembolism (VTE) treatment in adults. However, in all phase-III trials children or adolescents have not been included. For under-aged VTE patients, current standard treatment consists of low molecular weight heparin or Vitamin K antagonists.
S. Gehrisch, J. Beyer-Westendorf
openaire +3 more sources
Pituitary apoplexy and rivaroxaban
Pituitary, 2017Pituitary apoplexy (PA), defined by the occurrence of a massive hemorrhagic necrotic rearrangement within a pituitary adenoma, is rare. Its occurrence can be associated with certain risk factors, including anticoagulation. We report the first case of PA with rivaroxaban which is one of the new oral anticoagulants: a 73 year-old patient presenting with ...
B. Chaufour-Higel +6 more
openaire +3 more sources
Italian Registry in the Setting of Atrial Fibrillation Ablation with Rivaroxaban - IRIS.
Minerva cardiology and angiologyBACKGROUND Catheter ablation (CA) of atrial fibrillation is routinely used to obtain rhythm control. Evidence suggest that catheter ablation should be done during uninterrupted oral anticoagulation.
Carlo Lavalle +15 more
semanticscholar +1 more source
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
New England Journal of Medicine, 2012 Harry R Büller +2 more
exaly +2 more sources